{"denoms":[{"counts":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"356"}],"units":"Participants"}],"groups":[{"description":"Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \\[First infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).","id":"BG000","title":"Obinutuzumab + Chlorambucil (GClb)"},{"description":"Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.","id":"BG001","title":"Chlorambucil (Clb)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"68"}]}],"title":"<65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"196"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"288"}]}],"title":">=65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"141"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"215"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Baseline measures are based on the participants who were included in the Stage 1a analysis."}